Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026

Unicycive Therapeutics, Inc.

2026-Q1 EPS reported -$0.54

Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.
Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.
FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.
R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.
Commercial readiness activities ongoing for potential OLC launch after PDUFA.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001213900-26-054736

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.